Leerink analyst David Risinger initiated coverage of Tenax Therapeutics (TENX) with an Outperform rating and $16 price target The firm expects shares to rise as the investment community comes to better appreciate the company’s lead asset, TNX-103, which is in Phase 3 for PH-HFpEF, or pulmonary hypertension due to heart failure with preserved ejection fraction. Further, Leerink argues that key asset TNX-103 has multibillion dollar sales potential, and it forecasts unadjusted worldwide 2036 sales of $2.2B and 30% probability-adjusted sales of $670M.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX: